Did AI cause the Biocryst Pharmaceuticals INC layoffs?

Stated reason: of the Original Report. The Original Report otherwise remains unchanged. Item 2.05. Costs Associated with Exit or Disposal Activities. On June 29, 2026, the Company announced its plan to discontinue the Company’s internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama (the “Plan”) as part of the Company’s ongoing strategic evolution to strengthen its rare disease pipel…

Why 3: Plant, store or site closure · Drivers: contrary evidence −0.7, industry AI exposure +0.5

Evidence: SEC filing, state WARN notice. Signals: attribution 0.0, primary source 0.0, exec statement 0.0, role exposure 0.653, industry exposure 0.712, AI investment 0.0, contrary evidence 0.4 · typical Health Care & Pharma roles (no roles named)

Headcount basis: WARN (sum of state notices; company-wide total not disclosed) · WARN: 47 workers at 1 site notice(s)

Stated reason: On June 25, 2026, the Board of Directors of BioCryst Pharmaceuticals, Inc. (the “Company”) approved a plan to discontinue the Company’s internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama (the “Plan”). The Plan was approved as part of the Company’s ongoing strategic evolution to strengthen its rare disease pipeline, following a comprehensive strategic review and sc…

Why 3: Plant, store or site closure · Drivers: contrary evidence −0.7, industry AI exposure +0.5

Evidence: SEC filing. Signals: attribution 0.0, primary source 0.0, exec statement 0.0, role exposure 0.761, industry exposure 0.712, AI investment 0.0, contrary evidence 0.4 · named roles: Computer and Information Systems Managers, General and Operations Managers

Headcount basis: not disclosed